Arcus Biosciences, Inc. Increase (Decrease) in Other Accrued Liabilities
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Other Accrued Liabilities of -$4.13 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2022-11-02
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2022-09-30 was $6.09M, a 23.81% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2022-06-30 was -$1.76M, a 181.01% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2022-03-31 was -$8.46M.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2021-12-31 was $5.06M, a 139.85% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2021 was $10.14M, a 120.73% increase from fiscal 2020.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2020 was $4.59M, a 163.51% increase from fiscal 2019.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2019 was $1.74M, a 6.99% decline from fiscal 2018.
- Arcus Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2018 was $1.87M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2022-09-30 | $6.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $4.33M derived: sum of 2 quarters · filed 2022-11-02 | -$4.13M 10-Q · filed 2022-11-02 | $926.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$10.22M 10-Q · filed 2022-08-03 | -$5.16M derived: sum of 3 quarters · filed 2022-08-03 | -$245.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | -$8.46M 10-Q · filed 2022-05-09 | -$3.41M derived: sum of 2 quarters · filed 2022-05-09 | $1.51M derived: sum of 3 quarters · filed 2022-11-02 | $3.68M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $5.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $9.97M derived: sum of 2 quarters · filed 2022-11-02 | $12.14M derived: sum of 3 quarters · filed 2022-11-02 | $10.14M 10-K · filed 2022-02-23 |
| 2021-09-30 | $4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $7.09M derived: sum of 2 quarters · filed 2022-11-02 | $5.08M 10-Q · filed 2022-11-02 | $7.19M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $163.00K 10-Q · filed 2022-08-03 | $2.27M derived: sum of 3 quarters · filed 2022-08-03 | $4.09M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | -$2.01M 10-Q · filed 2022-05-09 | $101.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.93M derived: sum of 3 quarters · filed 2022-05-09 | $4.16M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $3.93M derived: sum of 2 quarters · filed 2022-02-23 | $6.17M derived: sum of 3 quarters · filed 2022-02-23 | $4.59M 10-K · filed 2022-02-23 |
| 2020-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $4.06M derived: sum of 2 quarters · filed 2021-11-08 | $2.48M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $661.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$1.58M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $1.74M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | $1.87M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |